Timo Minssen
Professor
JUR Center for Advanced Studies in Bioscience Innovation Law
Karen Blixens Plads 16
2300 København S
en store løsning hedder vaccine. Så her er det hækkeløb af forhindringer, vi skal over, før vi har sådan en
23/04/2020
1 Media contribution
Press/Media: Press / Media
Why the GMO Regulations in Europe are ‘Not Fit for Purpose’
27/02/2019
1 Media contribution
Press/Media: Press / Media
Ukraine medicine IP waiver becomes ‘matter of life or death’
16/06/2022
1 Media contribution
Press/Media: Press / Media
USA sætter jagten ind på industrien, (interview concerning EU and US procedures regarding pharmaceutical patent settlements).
08/01/2014
1 Media contribution
Press/Media: Press / Media
US reform plan for patents raises innovation concerns
09/07/2019
1 Media contribution
Press/Media: Press / Media
Topadvokats selvmord kan sende medicinspekulanter på pengejagt
17/05/2017
1 Media contribution
Press/Media: Press / Media
That Pill Is Watching You - Privacy And Hackability Of Ingestible Electronic Sensors
Sara Gerke, Timo Minssen, Helen Yu & Glenn Cohen
03/09/2019
1 item of Media coverage
Press/Media: Press / Media
Små firmaer kan få et vanskeligt liv under den nye patentdomstol.
10/04/2014
1 Media contribution
Press/Media: Press / Media
Settling the conflict between public health and liberty once and for all
30/08/2020
1 Media contribution
Press/Media: Press / Media
Sara Gerke and Timo Minssen join Diana Samuel to discuss the European Commission’s white paper on artificial intelligence (published in February 2020), and the challenges of implementing the outlined approach in healthcare.
Timo Minssen & Sara Gerke
11/06/2020
1 Media contribution
Press/Media: Press / Media
Salg af vaccineproduktion har gjort os sårbare
16/03/2020
1 Media contribution
Press/Media: Press / Media
SWEDEN’s Response to COVID-19: A tale of trust, recommendations, and odorous nudges
12/05/2020
1 Media contribution
Press/Media: Press / Media
Professor: En coronavaccine skal udvikles hurtigt, men vi kan ikke slække for meget på sikkerheden
23/03/2020
1 Media contribution
Press/Media: Press / Media
Professor i sundhedsret: Er vi trygge ved at vaccineproduktion er ude af vores hænder?
19/03/2020
1 Media contribution
Press/Media: Press / Media
Preparing for Antimicrobial Resistance: Vision and Social Science Mission of the INAMRSS Network
11/12/2020
1 Media contribution
Press/Media: Press / Media
Podcast-interview: Unlocking the full potential of Open Innovation in the Life Sciences through a classification system, see: https://www.ebe-biopharma.eu/wp-content/uploads/2018/01/EBE_Open-Innovation-Podcast-3.mp3
Timo Minssen & Niclas Nilsson
14/12/2017
1 Media contribution
Press/Media: Press / Media
Pharma companies need data strategies more than ever following recent CJEU decisions
04/02/2020
1 Media contribution
Press/Media: Press / Media
On antibiotics, capital gains, China, America’s civil war, unicorns, ties - Letters to the editor
Jonathan Darrow & Timo Minssen
25/05/2019
1 Media contribution
Press/Media: Press / Media
Når man blander kunstig intelligens med biomedicin, så er juraen essential - Interview with CeBIL Director Timo Minssen
11/10/2018
1 Media contribution
Press/Media: Press / Media
Novo vingeskudt i patentslagsmål: Berlingske Business
15/03/2016
1 Media contribution
Press/Media: Press / Media
Novo styrer mod overraskende sejr i patentkrig: Berlingske Business
29/06/2016
1 Media contribution
Press/Media: Press / Media
Novo kaster millioner efter retsopgør med Kåre Schultz og Teva
Timo Minssen & Karin Beukel
17/01/2018
1 Media contribution
Press/Media: Press / Media
Mixed views on Broad’s fate after EPO revokes CRISPR patent
18/01/2018
1 Media contribution
Press/Media: Press / Media
Medicinalindustri vil fortsat skjule oplysninger om forsøg
01/02/2018
1 Media contribution
Press/Media: Press / Media
Los secretos comerciales, un obstáculo para la producción de una vacuna contra la Covid-19
14/08/2020
1 Media contribution
Press/Media: Press / Media
Locus licenses CRISPR tech to Janssen in potential $818m deal
09/01/2019
1 Media contribution
Press/Media: Press / Media
LSPN Europe 2017: Broad had ‘no clue’ about CRISPR licensing in agriculture
07/12/2017
1 Media contribution
Press/Media: Press / Media
Key takeaways from IAM’s 2020 Pharma and Biotech IP event
06/02/2020
1 Media contribution
Press/Media: Press / Media
Interview with Danish Radio (DR) on compulsory licensing issues
12/02/2021
1 Media contribution
Press/Media: Press / Media
Interview on the Role of Patents and Licensing in the Governance of Human Genome Editing
01/06/2021
1 Media contribution
Press/Media: Press / Media
Interview for WHO: Regulating digital health
01/04/2020
1 Media contribution
Press/Media: Press / Media
Influencer Dies After Drinking Pesticide During Livestream As Viewers Encouraged Her Suicide
Karen Celedonia, Marcelo Corrales Compagnucci, Michael Lowery Wilson & Timo Minssen
18/10/2021
1 item of Media coverage
Press/Media: Press / Media
In Conversation With... Sara Gerke and Timo Minssen
23/06/2020
1 Media contribution
Press/Media: Press / Media
German court blocks approval of European patent system
20/03/2020
1 Media contribution
Press/Media: Press / Media
Genpatent avvisas av EUs patentverk: Europeiska patentmyndigheten, EPO, godkänner inte amerikanska Myriad Genetics patentansökan för diagnos av bröstcancergenen BRCA1.Men segern är ännu inte vunnen
01/06/2004
1 Media contribution
Press/Media: Press / Media
Gennemsigtighed i menneskeforsøg kan standse udvikling af ny medicin
30/06/2016
1 Media contribution
Press/Media: Press / Media
GSK's selvmordssag kan sætte gang i medicinspekulanter
17/05/2017
1 Media contribution
Press/Media: Press / Media
GMO Regulations in Europe Are “Not Fit for Purpose”
11/11/2020
1 Media contribution
Press/Media: Press / Media
Flere firmaers patenter er i farezonen efter omstridt EU-dom: Selskaber, der har fået patent på forskning med visse stamceller, risikerer at komme til at stå med et ugyldigt patent i hånden
22/03/2012
1 Media contribution
Press/Media: Press / Media
European Unified Patent Court plans for life after Brexit
19/03/2020
1 Media contribution
Press/Media: Press / Media
ID: 16150437
Most downloads
-
4329
downloads
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar? – Del 1: – Om nyare utvecklingar kring kravet på ’industrial application’ och ’utility’ för gen- och proteinrelaterade uppfinningar i USA och Europa
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
2191
downloads
The Evolution of the CJEU’s Case Law on Stem Cell Patents: Context, Outcome and Implications of Case C‑364/13 International Stem Cell Corporation.
Research output: Contribution to journal › Journal article › Research › peer-review
Published -
2078
downloads
När anses en bioteknologisk uppfinning vara komplett och praktiskt användbar? – Del 2: Om nyare utvecklingar kring kravet på ’industrial application’ och ’utility’ för gen- och proteinrelaterade uppfinningar i USA och Europa
Research output: Contribution to journal › Journal article › Research › peer-review
Published